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Background: West Nile virus (WNV) belonging to the genus Flavivirus of the family Flaviviridae causes nervous
system disorder in humans, horses and birds. Licensed WNV vaccines are available for use in horses but not for
humans. We previously developed an inactivated West Nile virus vaccine (WN-VAX) using a seed virus from West
Nile virus (WNV NY99) that was originally isolated in New York City in 1999. In this study, we report the
immunogenicity of WN-VAX in both mice and non-human primates.
Findings: The WN-VAX immunized mice showed protection against lethal infection with WNV NY99. The challenge
test performed on mice passively immunized with serum from other mice that were previously immunized with
WN-VAX confirmed that the neutralizing antibody titers of more than 1log10 protected the passively immunized
mice from WNV lethal infection. Furthermore, monkeys (Macaca fascicularis) immunized three times with 2.5 μg,
5 μg or 10 μg/dose of WN-VAX exhibited neutralizing antibodies in their sera with titers of more than 2log10 after
the second immunization.
Conclusions: The WN-VAX was protective in mice both by active and passive immunizations and was immunogenic
in monkeys. These results suggest that the vaccine developed in this study may be a potential WNV vaccine candidate
for human use.
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Background
West Nile virus (WNV) belonging to the genus Flavivi-
rus of the family Flaviviridae has caused sporadic dis-
ease epidemics in Africa, Europe, Middle East and West
Asia. Until the end of the 1990s, WNV disease was not
taken seriously because it was believed to be a mild fe-
brile infection. Later, this virus was found to be highly
pathogenic to humans, horses and birds. A strain of this
virus that spread in New York over a short period of
time was isolated [1]. This strain has caused high rates
of nervous system disorder and mortality, particularly in
the elderly population [2].
There are commercially available licensed WNV vac-
cines for horses, but there are currently none available for
humans. Candidate vaccines, such as the chimera vaccine* Correspondence: yokuno@mail.biken.or.jp
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unless otherwise stated.with YFV, inactivated vaccine and DNA vaccine, for hu-
man use are still under development (Table 1) [3-6].
We previously reported the development of an inacti-
vated and preservative-free WNV vaccine (WN-VAX)
for human use. The method used for the production of
this vaccine candidate was similar to that used to pro-
duce the cell-culture-derived inactivated Japanese en-
cephalitis (JE) vaccine [7,8]. In this study, we report the
immunogenicity of WN-VAX in both mice and non-
human primates.
Materials and methods
Inactivated West Nile vaccine and neutralizing antibody
titer (NAT) determination
The WNV strain (NY99-35262-11), which was isolated
from a flamingo in New York in 1999, was used to pre-
pare WN-VAX in Vero cells [8]. The ddY mice and the
monkeys (Macaca fascicularis) used in this study were
obtained from Japan SLC, Shizuoka, Japan. The NATs of
the serum of immunized animals against WNV wereThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with some modifications [9,10].
Challenge of WN-VAX immunized mice
Four-week-old female mice were divided into five groups
(n = 10 per group). All of the members of each group
were immunized subcutaneously with 0.5 ml of WN-
VAX at a specific concentration from a four-fold dilution
series (0.313, 0.078, 0.02, 0.005 and 0.001 μg/dose) with
phosphate-buffered saline not containing calcium and
magnesium but containing 0.02% gelatin as the diluent.
A control group of 10 mice was left untreated.
Immunization was performed twice with a seven-day
interval. Seven days after the second immunization, both
the immunized and the non-immunized mice were chal-
lenged intraperitoneally with 2.7 × 107 PFU of WNV
NY99 per mouse (108.46 LD50). The survival of the mice
was observed for 21 days, and the survival rate per
group was computed.
Challenge and NATs of passively immunized mice
To obtain antisera, four-week-old female mice were im-
munized twice with 5 μg of WN-VAX at seven-day
interval. One week after the second immunization,
serum samples were collected, pooled (1:1) and diluted
in a four-fold series (1:4, 1:16, and 1:64). For passive
immunization, 0.5 ml of undiluted or diluted sample was
administered subcutaneously into each member of four
groups (n = 15 per group) of six-week-old female mice.
A control group of 10 mice was not immunized. After
24 hours, 10 out of 15 passively immunized mice per
group and all of the control mice were challenged with6.4 × 103 PFU of WNV NY99 per mouse (103.65 LD50),
whereas serum samples from the five remaining unchal-
lenged passively immunized mice from each group were
collected for the determination of NATs against WNV
NY99. The NATs for the serum samples from the mice
that served as sources of passive immunization were also
determined. The mortality of the challenged mice was
then observed over a period of 21 days.
Immunogenicity of WN-VAX in monkeys
Ten female five-year-old monkeys were divided into
three groups (n1 = 4, n2 = 3, n3 = 3), and each group was
immunized subcutaneously with 2.5 μg, 5 μg, and 10 μg
per dose, respectively. The monkeys were immunized on
day 0 and on days 14, and 35. Serum from each monkey
was collected before immunization and 7, 14, 21, 28, 35,
42, 49, and 56 days after the first immunization and
checked for NATs against WNV NY99.
Statistical analysis
The murine survival curves were compared with the
challenge group using the logrank test. Differences were
considered statistically significant when P <0.05 by the
Dunnett-Hsu multiple comparison test. In monkeys,
statistical analysis was performed using Microsoft Excel
2000, and the P values were calculated through the
paired Student’s t-test.
Ethical approval
The experiments were performed in accordance with internal
procedures and were approved by the Institutional Animal
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Microbial Diseases of Osaka University.
Results
Protective efficacy of WN-VAX in mice
Mice immunized with WN-VAX were protected from le-
thal challenge with WNV NY99. The survival rate was
correlated with the immunization dose of WN-VAX. The
survival rate was 100% at a concentration of WN-VAX of
at least 0.078 μg/dose (Figure 1). We observed no clinical
signs in the surviving mice. None of the non-immunized
mice survived the challenge.
Protective efficacy of WN-VAX induced neutralizing anti-
body in passively immunized mice
The NATs in the undiluted (1:1) and the serially diluted
(1:4, 1:16 and 1:64) serum samples of WN-VAX immu-
nized mice were 2.62, 2.09, 1.65 and 1.01log10, respect-
ively. The survival rates of the groups of mice (Groups
1, 2, 3 and 4) passively immunized with these immune
sera and infected with lethal WNV 24 hours post-
immunization were 100% in the first three groups and
30% in the last group. In Group 3, only one mouse was
NAT-positive against WNV, and the rest were negative
(under the detection limit). None of the control mice sur-
vived after lethal infection with WNV (Table 2, Figure 2).
Immunogenicity of WN-VAX in monkeys
All of the immunized monkeys, with the exception of
one (non-responder) belonging to the group adminis-
tered 10 μg/dose of WN-VAX, had more than 1log10
NATs after receiving a single dose of WN-VAX. All of
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Figure 1 Survival rate of WN-VAX immunized mice and control. Five g
0.078 (x/pale blue), 0.02 (▲/blue gray), 0.005 (●/sky blue) and 0.001 (○/light pu
(■/red, n = 10) was left untreated. Seven days after the second immunization, b
WNV NY99, and their survival was observed for 21 days thereafter. The survival
WN-VAX. P values were calculated using the Dunnett-Hsu multiple comparison t
with 0.313, 0.078, 0.02, 0.005 and 0.001 μg/dose of WN-VAX were 21.0., 21.0, 18.8,2log10 NATs after the second immunization. The geo-
metric mean titers (GMTs) were calculated using the
data from seropositive monkeys in each group. The
GMTs reached a plateau at a value of more than 2log10
after the monkeys received the vaccine for the second
time (Figure 3).
Discussion
Our previous study showed that the WN-VAX developed
by our laboratory is immunogenic in mice, is capable of
eliciting neutralizing antibodies in mice and can protect
WNV-immunized mice from lethal WNV infection [8].
Here, we showed that the vaccine is protective in mice
through not only active but also passive immunization
and is also immunogenic in monkeys.
A previous study reported that hamsters passively im-
munized with the sera from other hamsters receiving the
inactivated WNV vaccine for horses were protected from
lethal infection with WNV [11]. In our study, we applied
the 50% plaque reduction assay for measuring the NATs
against WNV NY99. This method, which is recom-
mended by the WHO for testing the potency of the JE
vaccine, has a cut-off value of 1log10 for seroprotection
[10]. We noted that the NATs in the serum of one
mouse from a group (Group 3, Table 2) that received the
WN-VAX immune serum at a NAT of 1.65log10 were
1.03log10, and the corresponding values in the other
groups were less than that recommended for seroprotec-
tion against JEV [10,12]. Despite the low NATs, all of the
mice in Group 3 survived the challenge, which suggests
that WNV lethal infection is preventable in mice as long
as the antiserum used for passive immunization has a











roups of mice (n = 10/group) were immunized twice with 0.313 (□/black),
rple) μg/dose of WN-VAX at an interval of seven days. The control group
oth the immunized and the control groups of mice were challenged with
rate increased correspondingly with an increase in the concentration of
est. The arithmetic means of survival time for the groups of mice immunized






1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21















Figure 2 Survival rates of passively immunized mice and control. Four groups of mice (n = 10/group) were passively immunized with serum
with NAT titers of 2.62 (□/sky blue, group 1), 2.09 (x/dark blue, group 2), 1.65 (○/navy blue, group 3) and 1.01 log10 (●/pale blue, group 4). The
NATs from the passively immunized mice are shown in Table 2. The control group (■/red, n = 10) was left untreated. Twenty-four hours after serum
administration, both the immunized and the control groups of mice were challenged with WNV NY99, and their survival was observed for 21 days
thereafter. All of the passively immunized mice in groups 1, 2 and 3 survived. P values were calculated using Dunnett-Hsu multiple comparison
test. *P <0.05.
Table 2 Neutralizing antibody titers (NATs) and survival rates in mice
Group NATs in pooled seruma of WN-VAX
immunized mice (serum dilution)
NATs in serum of of individual mouseb 24 hrs
after passive immunization
Survival rate of passively immunized micec
after challenge with WNV NY99




















Control Not tested 0% (0/10)
aused for passive immunization of mice in Groups 1, 2, 3 and 4.
bOnly 5 mice per experimental group had their serum determined for NATs. These mice were not subjected to virus challenge and were used only for a
representative determination of NATs in the group.
cNATs of their serum were not determined because no blood sampling was done to avoid stressing the animals during virus challenge.
dNAT log10.
enumber enclosed in parentheses refer to the number of surviving mice/total no. of mice.
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Figure 3 Neutralization titers in the groups of monkeys immunized with WN-VAX. Geometric mean neutralization titers (GMT) in the groups
of monkeys immunized with 2.5 μg/dose (▲), 5 μg/dose (■) or 10 μg/dose (●) of WN-VAX. NATs from the serum of each monkey immunized with
2.5 μg/dose (Δ), 5 μg/dose (□) or 10 μg/dose (○). In the groups that received 5 μg/dose and 10 μg/dose WN-VAX, the NATs reached a plateau after
the second immunization. The arrow points to the day of WN-VAX immunization. P values were calculated using the paired Student’s t-test against the
NAT from the monkeys at day 0 before immunization. *P <0.05.
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titers of antibodies against WNV has therapeutic effects
on patients with neurological disorder caused by WNV in-
fection [13-15]. However, there are no reports on the use
of these antibodies for preventive purposes in humans.
WNV, similarly to JEV, belongs to the JE serocom-
plex. The WN-VAX in this study was produced based
on the procedure for the production of inactivated JE
vaccine (JEBIK V® The Research Foundation for Micro-
bial Diseases of Osaka University). Epidemiological evi-
dence in a JE-endemic area suggests that the JE vaccine
may be effective for protecting people from JE disease,
and the challenge test with the inactivated JE vaccine
demonstrated that NATs of more than 1log10 can pre-
vent mice from the onset of illness [12]. NATs of more
than 1log10 were also found to be effective for protect-
ing humans from JEV infection [16]. The protective
mechanism provided by WN-VAX to an organism is
supposed to be similar to that of JEV, and the present
study demonstrated that the actively and the passively
immunized mice were protected from WNV lethal
infection. Thus, it is also possible that NATs of more
than 1log10 can protect human beings from WNV lethal
infection.
In monkeys, the NATs against WNV increased more
than 2log10 after at least two subcutaneous immuniza-
tions of WN-VAX, regardless of the immunization dose
(2.5 μg, 5 μg or 10 μg/dose). Because NATs of 1log10
protected mice from WNV lethal infection, WN-VAX
may also protect monkeys from this lethal infection at
the same NAT level. Given that the NATs against WNV
in monkeys with a dose of more than 5 μg/dose reached
a plateau after the second immunization, it is consideredthat, at least, a certain level of protective ability against
WNV infection was acquired three weeks after the first
immunization. Thus, three doses enabled those immu-
nized monkeys to maintain the level of NATs required
for protection from infection. Protection experiments in
monkeys are now considered for investigation.
While most cases of WNV infections are subclinical,
the elderly population shows a high incidence of serious
nervous disorders and thus a safe WNV vaccine is
needed. Our GLP test on WN-VAX indicates no safety
problems [8]. Clinical trials on the safety and efficacy of
WN-VAX on humans will be performed in our future
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